Endocytosis and Dynamin Inhibitors

This article provides an introduction to dynamin and endocytosis and lists the inhibitors that are relevant to research.

Dynamin is an important GTPase enzyme that takes part in different endocytotic processes. It has three major isoforms, and each of these is composed of four primary domains with different functions.

Another major role played by dynamin is in the regulation of the cell cycle. It also has a crucial role in the way centrosomes cohere and in cytokinesis.

Dynamin inhibitors are molecules that inhibit the action of different domains of the dynamin enzyme, and thus prevent the occurrence of endocytosis. They have found wide uses in such areas as the study of the pathways of cell signaling, the cell cycle, cell division, and illnesses such as cancer, infectious diseases, including botulism and HIV, and neurological conditions.

Dynamin Inhibitors

The following is a list of the dynamin inhibitors available:

Name   Description Publications featuring our products
Dynole 2-24™ EXCLUSIVE Novel, potent dynamin I and II inhibitor  
Dyngo4a™ EXCLUSIVE Novel, highly potent dynamin inhibitor. Dynasore (Asc-192) analog. View
Rhodadyn C10™ EXCLUSIVE Highly potent cell permeable dynamin I inhibitor  
Rhodadyn B10™ EXCLUSIVE Negative control for Rhodadyn C10™  
Dynole-34-2™ EXCLUSIVE Potent dynamin I and dynamin II inhibitor View
Dynole-31-2™ EXCLUSIVE Negative control for Dynole 34-2™ View
Pitstop 2™ EXCLUSIVE Novel, selective cell permeable clathrin inhibitor View
Iminodyn 17™   Negative control for Iminodyn-22™  
Iminodyn 22™   Potent, broad spectrum dynamin inhibitor  
RTIL-13™   Potent dynamin I and II inhibitor  
MiTMAB™   Cell permeable dynamin I and dynamin II inhibitor View
OctMab™   Cell permeable dynamin I and dynamin II inhibitor  
Pro-myristic acid   Negative control for MiTMAB™ and OcTMAB™  
Dynamin Inhibitors Toolbox   Dynamin inhibitor kit from the MiTMAB™, Dynole™ and Iminodyn™ chemical series. View
Dynamin Inhibitors: Iminodyn™ Series Kit   Dynamin inhibitor kit from the Iminodyn™ series View
Dynamin Inhibitors: MiTMAB™ Series Kit   Dynamin inhibitor kit from the MiTMAB™ series View
Dynamin Inhibitors: Dynole™ Series Kit   Dynamin inhibitor kit from the Dynole™ series  

A Summary of Dynamin Inhibitor Activity

The following table shows how dynamin inhibitors work via different mechanisms:

Compound Target Domain Dynamin I Inhibition (μM) Dynamin II Inhibition (μM) Synaptic Vesicle Endocytosis (μM) Receptor Mediated Endocytosis (μM) Reference
Dynole-
2-24™
N/A 0.56 5.4 - - Gordon et al 2013
Dyngo-
4a™
N/A 380 nM 2.6 μM     Harper et al 2011
Dynole
-34-2™
GAS 1.3 14.2 41.1 5 Hill et al 2009
Dynole-31
-2™
GAS >300       Hill et al 2009
Rhodadyn C10™ N/A 7.1 - - - Robertson et al 2012
Rhodadyn B10™ N/A - - - - Robertson et al 2012
Iminodyn
-22™
GAS 450 nM 390 nM 108 10.7 Hill et al 2010
Iminodyn
-17™
GAS 330 nM 440 nM >300 >300 Hill et al 2010
RTIL-13™ PH 2.3   7.1 9.3 Zhang et al 2008
MiTMAB™ PH 3.1 8.4 2.2 19.9 Hill et al 2004
OcTMAB™ PH 1.9 4.4   6.7 Quan et al 2007
Pro-
Myrisitic Acid
PH 9.2     >300 Quan et al 2007
Dynamin Inhibitors Toolbox PH & GAS          
Dynamin Inhibitors: MiTMAB Series Kit PH          
Dynole Series Kit GAS          
Dynamin Inhibitors: Iminodyn Series Kit GAS          

References

  • Hill TA et al. Iminochromene inhibitors of dynamins I and II GTPase activity and endocytosis. J Med Chem 53:4094-102 (2010).
    Read more (PubMed: 20426422)
  • Hill TA et al. Inhibition of dynamin mediated endocytosis by the dynoles--synthesis and functional activity of a family of indoles. J Med Chem 25:3762-73 (2009).
    Read more (PubMed: 19459681)

Recommended Resources from Our Technical Team

  • Granseth B et al. Clathrin mediated endocytosis: the physiological mechanism of vesicle retrieval at hippocampal synapses. J Physiol 15:681-6 (2007).
    Read more (PubMed: 17599959)
  • Mettlen M et al. Dissecting dynamin's role in clathrin-mediated endocytosis. Pharmacol Ther 47:233-66 (2009)
    Read more (Pubmed: 1975444)

About Abcam

Abcam is a global life sciences company providing highly validated antibodies and other binders and assays to the research and clinical communities to help advance the understanding of biology and causes of disease.

Abcam’s mission is to serve life scientists to help them achieve their mission faster by listening to their needs, continuously innovating and improving and by giving them the tools, data and experience they want. Abcam’s ambition is to become the most influential life science company for researchers worldwide.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jan 30, 2020 at 5:38 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Abcam. (2020, January 30). Endocytosis and Dynamin Inhibitors. News-Medical. Retrieved on November 21, 2024 from https://www.news-medical.net/whitepaper/20190124/Endocytosis-and-Dynamin-Inhibitors.aspx.

  • MLA

    Abcam. "Endocytosis and Dynamin Inhibitors". News-Medical. 21 November 2024. <https://www.news-medical.net/whitepaper/20190124/Endocytosis-and-Dynamin-Inhibitors.aspx>.

  • Chicago

    Abcam. "Endocytosis and Dynamin Inhibitors". News-Medical. https://www.news-medical.net/whitepaper/20190124/Endocytosis-and-Dynamin-Inhibitors.aspx. (accessed November 21, 2024).

  • Harvard

    Abcam. 2020. Endocytosis and Dynamin Inhibitors. News-Medical, viewed 21 November 2024, https://www.news-medical.net/whitepaper/20190124/Endocytosis-and-Dynamin-Inhibitors.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.